Tol Trimborn
Investor
Netherlands
Invests in
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- SU
- SU
- EU
- LU
Lists including Tol
Work Experience
2016 - 2024
Venture Partner
2016 - 2024
2020 - 2023
Chief Executive Officer
2020 - 2023
2015 - 2020
COO
2015 - 2020
Gadeta B.V. is a Research & Development company established in 2015, which focusses on the development of innovative immunotherapies for cancer. The work of the company is based on the groundbreaking discoveries regarding the role of γδ T cell receptors (TCR’s) in the broad recognition of heamatological and solid tumour cells and their potential use for the treatment of advanced malignancies as discovered by Prof. Jürgen Kuball at the University Medical Centre Utrecht (UMCU), The Netherlands.
2008 - 2015
CEO
2008 - 2015
2010 - 2014
Voorzitter bestuur Gooilandschool
2010 - 2014
2005 - 2008
General manager
2006 - 2008
Director Corporate Development
2005 - 2006
2006 - 2008
Senior director commercial development
2006 - 2008
2001 - 2005
Associate
2001 - 2005